ARDX · Ardelyx, Inc. · Executive Compensation

$3.21 +0.12 (+3.88%)

Russell 2000 member Rebalance outlook locked

Market Cap

$797.40M

249.19M

Volume · Oct 20 3.95M Avg daily vol (3M) 4.34M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Michael Raab	President, Chief Executive Officer and Director	$797,000	—	$2,953,724	$3,413,948	$627,638	$3,861	$7,796,171
Edward Conner	Former Chief Medical Officer	$213,019	—	$1,574,775	$1,836,116	—	—	$3,623,910
Justin Renz	Former Chief Financial and Operations Officer	$464,434	—	$1,578,559	$1,182,722	$250,425	$75,543	$3,551,684
Susan Hohenleitner	Chief Financial Officer	$120,929	$330,000	$735,949	$2,194,078	$56,416	—	$3,437,372
John Bishop	Chief Technical and Quality Officer	$240,000	—	$1,004,980	$1,148,032	$116,510	$3,000	$2,512,522
Elizabeth Grammer	Former Chief Legal and Administrative Officer	$527,126	—	$708,002	$818,313	$246,695	$3,481	$2,303,617

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Michael Raab	President, Chief Executive Officer and Director	$770,000	—	$4,170,500	$4,164,621	$495,880	$5,164	$9,606,165
Michael Kelliher	EVP, Corporate Development and Strategy	$338,461	—	$1,232,000	$1,238,303	$182,160	—	$2,990,924
Justin Renz	Chief Financial and Operations Officer	$517,000	—	$1,121,645	$1,127,238	$214,038	$3,932	$2,983,853
Elizabeth Grammer	Chief Legal and Administrative Officer	$509,300	—	$1,121,645	$1,127,238	$210,850	$4,273	$2,973,306
Laura Williams	M.D., M.P.H. Chief Medical Officer	$522,720	—	$1,042,625	$1,045,630	$216,406	—	$2,827,381

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Michael Raab	President, Chief Executive Officer and Director	$700,000	$330,000	$687,500	$2,395,694	—	$4,950	$4,118,144
Elizabeth Grammer	Chief Legal and Administrative Officer	$463,300	$200,000	$214,500	$748,121	—	$4,950	$1,630,871
Laura Williams	M.D., M.P.H. Chief Medical Officer	$483,600	$181,210	$214,500	$748,121	—	—	$1,627,431

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Michael Raab	President, Chief Executive Officer and Director	$650,000	$300,000	$148,500	$517,020	$331,500	—	$1,947,020
Laura Williams	M.D., M.P.H. Chief Medical Officer	$465,000	$250,000	$39,600	$141,811	$158,800	—	$1,055,211
Susan Rodriguez	Chief Commercial Officer	$455,800	$150,000	$139,590	$144,027	$154,972	—	$1,044,389

Fiscal 2021

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Michael Raab	President, Chief Executive Officer and Director	$650,000	$195,000	$1,105,898	$2,085,096	$195,000	—	$4,230,994
Elizabeth Grammer	Chief Legal and Administrative Officer	$445,500	$89,100	$519,586	$590,777	$89,100	—	$1,734,063
Justin Renz	Chief Financial Officer	$445,500	$89,100	$519,586	$590,777	$89,100	—	$1,734,063
Robert Blanks	Chief Regulatory Affairs and Quality Assurance Officer	$422,000	$84,400	$519,586	$590,777	$84,400	—	$1,701,163
David Rosenbaum	Chief Development Officer	$461,000	$92,200	$394,586	$590,777	$92,200	—	$1,630,763

Fiscal 2020

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Michael Raab	President, Chief Executive Officer and Director	$633,333	—	—	$3,006,326	$314,325	—	$3,953,984
Susan Rodriguez	Chief Commercial Officer	$273,589	—	$154,000	$1,250,007	$145,200	—	$1,822,796
Justin Renz	Chief Financial Officer	$242,839	$10,000	$73,500	$1,000,008	$141,900	—	$1,468,247

Fiscal 2019

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Michael Raab	President, Chief Executive Officer and Director	$595,000	—	—	$740,922	$393,000	—	$1,728,922
David Rosenbaum	Chief Development Officer	$428,250	—	—	$195,408	$189,000	—	$812,658
Elizabeth Grammer	Chief Legal and Administrative Officer	$414,000	—	—	$195,408	$182,000	—	$791,408

Fiscal 2018

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Michael Raab	President & Chief Executive Officer	$575,000	—	$860,000	$2,541,683	$205,563	—	$4,182,246
David Rosenbaum	Chief Development Officer	$414,000	—	$430,000	$760,156	$107,640	—	$1,711,796
Elizabeth Grammer	Chief Legal and Administrative Officer	$400,000	—	$430,000	$760,156	$104,000	—	$1,694,156

Executive changes

Person	Role	Change	Effective	Filed
Edward Conner, M.D.	Chief Medical Officer	Resigned	2025-12-31	2025-12-17
Elizabeth Grammer	Chief Legal and Administrative Officer	Resigned	2025-12-31	2025-12-17
Sue Hohenleitner	chief financial officer ("CFO") and principal financial officer	Appointed	2025-11-04	2025-10-14
James P. Brady	Chief Human Resources Officer	Appointed	—	2025-08-04
Mike Kelliher	Chief Business Officer	Appointed	—	2025-08-04
Michael Raab	Class II Director	Appointed	2025-06-18	2025-06-18
David Mott	Class II Director	Appointed	2025-06-18	2025-06-18
Merdad Parsey, M.D., Ph.D	member of the Nominating and Corporate Governance Committee of the Board	Appointed	2025-06-18	2025-04-29
Merdad Parsey, M.D., Ph.D	member of the Board of Directors	Appointed	2025-04-28	2025-04-29
Joseph Reilly	Principal Accounting Officer	Appointed	2024-11-15	2024-11-18
Onaiza Cadoret-Manier	Class I director	Appointed	2024-06-14	2024-06-17
William A. Bertrand, Jr., Esq.	Class I director	Appointed	2024-06-14	2024-06-17
Geoffrey A. Block, M.D.	Board of Directors	Resigned	2023-11-13	2023-11-13

Leadership

Michael Raab CEO, Board Member
Keith Santorelli CFO
Susan Hohenleitner CFO
Joseph Reilly Chief Accounting Officer
Justin Renz Chief Accounting Officer
Robert Felsch Chief Accounting Officer
David Mott Board Member
Merdad Parsey, M.D., Ph.D Board Member
Muna Bhanji Board Member
Muna Bhanji, R.Ph Board Member
Onaiza Cadoret-Manier Board Member
Richard Rodgers Board Member
Robert Bazemore Board Member
William A. Bertrand, Jr., Esq. Board Member

Key facts CIK 1437402 CUSIP 039697107 13F (30d) 16 filings 16 filers Visit website Investor relations